Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

https://doi.org/10.20996/1819-6446-2017-13-1-45-50

Full Text:

Abstract

Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both therapies on the healthcare budget of Russian Federation.

Material and methods. Pharmacoeconomic analysis with "decision tree" modeling is performed. The costs of regimens using rivaroxaban and apixaban were calculated. Assessment of the likelihood of cerebrovascular complications during anticoagulant therapy was performed, and the average additional costs in development of adverse  clinical effects were calculated. The average costs of treatment regimens used in view of the probability of occurrence of all the clinical effects,  were calculated as a result of the modeling.

Results. The results of the pharmacoeconomic analysis shown, that the strategy of the use of rivaroxaban for stroke prevention in patients with non-valvular AF is less costly 49558.43 rubles for one patient per year. The strategy of apixaban application costs higher by 0.15% (50027.57 rubles). Cost reduction for the year of rivaroxaban therapy in a cohort  of 1000 patients was 469140 rubles due to decrease in the incidence of cerebrovascular complications in comparison with apixaban therapy.

Conclusion. When choosing pharmacotherapy strategy to prevent the stroke in patients with non-valvular AF rivaroxaban use is more effective, than the use of apixaban, from the clinical and pharmacoeconomic points of view.

About the Authors

S. V. Nedogoda
Volgograd State Medical University
Russian Federation

Sergey V. Nedogoda – MD, PhD, Professor, Head of Chair of Therapy and Endocrinology, Faculty of Advanced Medical Education.

Tsiolkovsky ul. 1, Volgograd, 400001



I. N. Barykina
Volgograd State Medical University
Russian Federation

Irina N. Barykina – MD, PhD, Assistant, Chair of Therapy and Endocrinology, Faculty of Advanced Medical Education.

Tsiolkovsky ul. 1, Volgograd, 400001



A. S. Salasiuk
Volgograd State Medical University
Russian Federation

Alla S. Salasiuk – MD, PhD, Assistant, Chair of Therapy and Endocrinology, Faculty of Advanced Medical Education.

Tsiolkovsky ul. 1, Volgograd, 400001



V. O. Smirnova
Volgograd State Medical University
Russian Federation

Victoria O. Smirnova – MD, Fellow, Chair of Therapy and Endocrinology, Faculty of Advanced Medical Education.

Tsiolkovsky ul. 1, Volgograd, 400001



References

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. JAMA. 2001;285(18):2370-5.

2. Hobbs F.R., Taylor C.J., Jan Geersing G., et al.; group on behalf of the EPCCS (EPCCS) S working. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol. 2016;23(5):460-73.

3. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation. 2011;123(4):e18-e209.

4. Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Hear J. 2010;31(19):2369-429.

5. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.

6. Ericson L., Bergfeldt L., Bjrholt I. Atrial fibrillation: The cost of illness in Sweden. Eur J Heal Econ. 2011;12(5):479-87.

7. Freedman B., Potpara T.S., Lip G.Y.H. Stroke prevention in atrial fibrillation. Lancet (London, England). 2016;388(10046):806-17.

8. Parfenov V.A., Verbitskaya S.V. The risk factors and prevention of stroke in atrial fibrillation. Nevrologija, Nejropsihiatrija, Psihosomatika. 2014;(3):55—60. (In Russ.) [Парфенов ВА, Вербицкая СВ. Факторы риска и профилактика инсульта при фибрилляции предсердий. Неврология, Нейропсихиатрия, Психосоматика. 2014;(3):55—60].

9. Muraveva V.N., Karpova E.N. Modern concepts of risk factors and prevention of stroke (literature review). Mezhdunarodnyj Zhurnal Eksperimentalnogo Obrazovanija. 2014;(3-2):59-64. (In Russ.) [Муравьева В.Н., Карпова Е.Н. Современные представления о факторах риска и профилактики ОНМК (обзор литературы). Международный Журнал Экспериментального Образования. 2014; (3-2): 59-64].

10. Skvorcova V.I., Alekseeva G.S., Trifonova N.J. Analysis of medical organizational measures for prevention of strokes and rehabilitation of post-stroke conditions at the present stage. Social'nye Aspekty Zdorov'ja Naselenija. 2013;29(1):2. (In Russ.) [Скворцова В.И., Алексеева Г.С., Трифонова Н.Ю. Анализ медико-организационных мероприятий по профилактике инсультов и реабилитации постинсультных состояний на современном этапе. Социальные Аспекты Здоровья Населения. 2013;29(1):2].

11. Maksimov R.S., Dmitrieva R.V., Deomidov E.S., Maksimova I.D. Prevention of stroke in atrial fibrillation in the elderly. Byulleten' Meditsinskikh Internet-konferentsiy. 2015;5(3):176-8. (In Russ.) [Максимов Р.С., Дмитриева Р.В., Деомидов Е.С., Максимова И.Д. Профилактика инсульта при фибрилляции предсердий у пожилых пациентов. Бюллетень Медицинских Интернет-конференций. 2015;5(3):176-8].

12. Bjorck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8.

13. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31(8):967-75.

14. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507.

15. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.

16. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.

17. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.

18. Kakkar A.K., Mueller I., Bassand J.P., et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-9.

19. Camm A.J., Ambrosio G., Atar D., et al. Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF. Eur Heart J. 2015;36:745-6.

20. Coleman C.I., Antz M., Bowrin K., et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;1-7.

21. Gusev E.I., Skvorcova V.I., Stahovskaja L.V. The problem of stroke in the Russian Federation: the time of active cooperative action. Zhurnal Nevrologii I Psihiatrii im. S.S. Korsakova. 2007;107(8):1-11. (In Russ.) [Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журнал Неврологии и Психиатрии им. СС Корсакова. 2007;107(8):1-11].

22. The effectiveness of the Russian economy. Federal State Statistics Service. Available at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/efficiency/. Checked by Feb 2, 2017. (In Russ.) [Эффективность экономики России. Федеральная служба государственной статистики. Доступно на: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/efficiency/. Дата доступа: 02.02.2017].

23. Inflation Calculator. http://уровень-инфляции.рф/инфляционные_калькуляторы.aspx. Checked by: Feb 01, 2017. (In Russ.) [Инфляционный калькулятор. http://уровень-инфляции.рф/инфляционные_калькуляторы.aspx. Дата доступа: 01.02.2017].

24. Weinstein M.C., O’Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices Modeling studies. Value Heal. 2003;6(1):9-17.

25. The Industry Standard "The clinical and economic studies. General The "Order of the RF Ministry of Health from 27.05.2002 №163 with IST 91500.14.0001-2002. (In Russ.) [Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ОСТ 91500.14.0001-2002].


For citation:


Nedogoda S.V., Barykina I.N., Salasiuk A.S., Smirnova V.O. CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2017;13(1):45-50. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-1-45-50

Views: 279


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)